BBB-PET; Evaluation of [18F]MC225 to measure P-glycoprotein function in neurodegenerative disease

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518865-85-00

Enrollment

Registered

2024-12-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers Disease, Parkinson, sporadic Cerebral Amyloid Angiopathy

Brief summary

Regionale PET tracer uptake en influx waarden van [18F]MC225

Detailed description

CBF - cerebral blood flow values obtained with [15O]H2O PET MRI (vessel architecture) VAI measurements Arterial samples replaced with less invasive venous samples

Interventions

DRUG5-(1-(2-[18F] fluoroethoxy))-[3-(6

DRUG7-dimethoxy-3

DRUG4-dihydro-1H-isoquinolin-2-yl)-propyl]-5

DRUG6

DRUG7

DRUG8-tetrahydronaphthalen

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Regionale PET tracer uptake en influx waarden van [18F]MC225	—

Secondary

Measure	Time frame
CBF - cerebral blood flow values obtained with [15O]H2O PET MRI (vessel architecture) VAI measurements Arterial samples replaced with less invasive venous samples	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026